Problem: We investigated if the PROGINS mutation increases the risk of hepatitis E virus (HEV) infection in liver transplant recipients. PROGINS was analyzed through KASP assay; HEV serologies assessed via enzyme-linked immunosorbent assay and multiplex cytokine assays were evaluated in plasma with the ProcartaPlex human immunoassay. Seventy liver transplant recipients were evaluated, of which 23 (33%) were HEV immunoglobuln G (IgG)-positive (HEV+). The frequency of PROGINS in the HEV+ group was 34%, compared with 14% in those that were HEV IgG negative (HEV−). Cytokine measurements in a sub-set of samples from HEV+/PROGINS+ individuals showed decreased plasma levels of monokine induced by gamma interferon, a proliferation-inducing ligand, and stem cell factor, as well as increased levels of eotaxin-3 and interleukin-31 compared with those HEV−/PROGINS− samples. Our findings suggest an association between the PROGINS mutation and seropositivity for HEV in liver transplant recipients with consequent distorted cytokine levels.
Bibliographical noteFunding Information:
Supported by the American College of Gastroenterology (ACG‐CR‐033‐2016), Robert Wood Johnson Foundation (AMFDP), and NIH‐NCI R21 CA215883‐01A1 all to JDD.
Supported by the American College of Gastroenterology (ACG-CR-033-2016), Robert Wood Johnson Foundation (AMFDP), and NIH-NCI R21 CA215883-01A1 all to JDD.
© 2020 Wiley Periodicals LLC
- liver transplant
PubMed: MeSH publication types
- Journal Article